Guggenheim Downgrades The Honest Co. (HNST) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Guggenheim Downgrades The Honest Co. (HNST) to Neutral
March 25, 2022 5:25 AM EDT
Telsey analyst Dana Telsey lowered the price target on The Honest Co. (NASDAQ: HNST) to $12.00 (from $18.00) while maintaining a Outperform rating.... More
March 25, 2022 4:16 AM EDT
(Updated - March 25, 2022 8:00 AM EDT)
Jefferies analyst Stephanie Wissink downgraded The Honest Co. (NASDAQ: HNST) from Buy to Hold with a price target of $5.00 (from $11.00).
The analyst commented, "We are stepping to the sidelines, downgrading to Hold, to reevaluate the model... More
March 25, 2022 3:08 AM EDT
Morgan Stanley analyst Dara Mohsenian lowered the price target on The Honest Co. (NASDAQ: HNST) to $8.25 (from $9.00) while maintaining a Equalweight rating.... More
March 24, 2022 6:02 PM EDT
The Honest Company Inc. (NASDAQ: HNST) shares dropped around 20% after-hours following the companys Q4 results, with EPS of ($0.10) coming in worse than the consensus estimate of ($0.06).
Revenue grew 3% year-over-year to $80.4 million, compared to the consensus of $84.59 million, primarily due to... More
March 24, 2022 5:25 PM EDT
After-Hours Stok Movers:
MEI Pharma (NASDAQ: MEIP) 46% LOWER; FDA informed the companies of its position that a randomized trial is now needed to adequately assess drug efficacy and safety of PI3K inhibitor drug candidates
The Honest Company Inc. (NASDAQ: HNST) 20% LOWER; reported Q4 EPS of ($0.10), $0.04 worse than the... More
March 24, 2022 4:07 PM EDT
The Honest Company Inc. (NASDAQ: HNST) reported Q4 EPS of ($0.10), $0.04 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $80.4 million versus the consensus estimate of $84.59 million.
Full Year 2022 Outlook:
RevenueFull Year 2022 revenue is expected...
More
